<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768155</url>
  </required_header>
  <id_info>
    <org_study_id>OFORT001</org_study_id>
    <nct_id>NCT02768155</nct_id>
  </id_info>
  <brief_title>Evaluation of Amniotic Fluid Product in Knee Osteoarthritis</brief_title>
  <official_title>Protocol for the Clinical Evaluation Amniotic Fluid (AF) Product in Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating Amniotic Fluid compared to a Saline Placebo Injection in the treatment of
      subjects with osteoarthritic (OA) knee pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Pain</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence grade of OA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>AF 4.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amniotic Fluid 4.0ml dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF 2.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amniotic Fluid 2.0ml dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic Fluid 4.0ml dose</intervention_name>
    <description>Injection of Amniotic Fluid</description>
    <arm_group_label>AF 4.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic Fluid 2.0ml dose</intervention_name>
    <description>Injection of Amniotic Fluid</description>
    <arm_group_label>AF 2.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 30 years or older.

          2. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren
             Lawrence grading scale.

          3. Subject is willing and able provide informed consent and participate in all procedures
             and follow-up evaluations necessary to complete the study.

        Exclusion Criteria:

          1. Subject has active infection at the injection site.

          2. Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any
             other auto-immune disorders that could be the cause of their knee pain.

          3. BMI greater than 45 kg/m2

          4. Subject has received an intra-articular hyaluronic acid (HA) injection for the
             treatment of OA of the target knee within 3 months prior to screening.

          5. Subject has received a steroid or platelet rich plasma (PRP) injection for the
             treatment of OA of the target knee within 3 months prior to screening.

          6. Subject has had major surgery, arthroplasty or arthroscopy in the target knee within
             26 weeks of treatment or plans to have surgery in the target knee within 180 days of
             treatment.

          7. Subject is pregnant or plans to become pregnant within 180 days of treatment.

          8. Subject has used an investigational drug, device or biologic within 12 weeks prior to
             treatment.

          9. Subject has any significant medical condition that, in the opinion of the
             Investigator, would interfere with protocol evaluation and participation.

         10. Subject has a history of immunosuppressive or chemotherapy in the last 5 years

         11. Subject has autoimmune disease or a known history of having Acquired Immunodeficiency
             Syndrome (AIDS) or HIV

         12. Subject has had prior radiation at the site

         13. Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)

         14. Diagnosis of gout in the past 6 month

         15. Subject has a diagnosis of osteoarthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Fetterolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>MiMedx Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates, Inc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Foot, Ankle and Orthopedic Institute</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OA, Osteoarthritis, Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

